5 Best Healthcare Stocks For the Long Term

Page 5 of 5

1. Exelixis, Inc. (NASDAQ:EXEL)

PE Ratio (TTM): 17.39

Number of Hedge Fund Holders: 35

Alameda, California-based Exelixis, Inc. (NASDAQ:EXEL) is known for its treatment for medullary thyroid cancer. Exelixis, Inc. (NASDAQ:EXEL) is also working on products related to metastatic cancer. Earlier this month, Exelixis, Inc. (NASDAQ:EXEL) posted Q4 and 2022 guidance. For the last quarter of 2022, Exelixis, Inc. (NASDAQ:EXEL) expects its revenue to total $415 million, as compared to the analyst consensus of $415.86 million. For 2022, Exelixis, Inc. (NASDAQ:EXEL) sees its revenue to come in at $1.6 billion, versus the consensus of $1.6 billion. For 2023, Exelixis, Inc. (NASDAQ:EXEL)’s revenue is expected to fall between $1.775 billion to $1.875 billion, versus the consensus of $1.83 billion.

Hedge fund sentiment is strong for Exelixis, Inc. (NASDAQ:EXEL). As of the end of the September quarter, 35 out of the 920 hedge funds tracked by Insider Monkey reported having stakes in Exelixis, Inc. (NASDAQ:EXEL), compared to 28 funds in the previous quarter. The total value of these stakes was $35 million.

You can also take a peek at 12 Best Holding Company Stocks To Invest In and 12 Best Bid Data Stocks To Buy.

Page 5 of 5